MX9206628A - Ester de prolinaboronato y metodo para su preparacion. - Google Patents

Ester de prolinaboronato y metodo para su preparacion.

Info

Publication number
MX9206628A
MX9206628A MX9206628A MX9206628A MX9206628A MX 9206628 A MX9206628 A MX 9206628A MX 9206628 A MX9206628 A MX 9206628A MX 9206628 A MX9206628 A MX 9206628A MX 9206628 A MX9206628 A MX 9206628A
Authority
MX
Mexico
Prior art keywords
prolinaboronate
ester
preparation
prolinaboronate ester
Prior art date
Application number
MX9206628A
Other languages
English (en)
Inventor
Roger Snow
Terence A Kelly
Julian Adams
Simon Coutts
Clark Perry
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MX9206628A publication Critical patent/MX9206628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
MX9206628A 1991-11-22 1992-11-18 Ester de prolinaboronato y metodo para su preparacion. MX9206628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79614891A 1991-11-22 1991-11-22
US93619892A 1992-08-26 1992-08-26

Publications (1)

Publication Number Publication Date
MX9206628A true MX9206628A (es) 1993-05-01

Family

ID=27121696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9206628A MX9206628A (es) 1991-11-22 1992-11-18 Ester de prolinaboronato y metodo para su preparacion.

Country Status (17)

Country Link
EP (1) EP0641347A1 (es)
JP (1) JPH07501078A (es)
CN (1) CN1073946A (es)
AU (1) AU661362B2 (es)
CA (1) CA2123128A1 (es)
CZ (1) CZ124494A3 (es)
FI (1) FI942345A0 (es)
HU (1) HUT67937A (es)
IL (1) IL103817A0 (es)
MX (1) MX9206628A (es)
NO (1) NO941905L (es)
NZ (1) NZ245207A (es)
PT (1) PT101079A (es)
SI (1) SI9200332A (es)
SK (1) SK59294A3 (es)
TW (1) TW232697B (es)
WO (1) WO1993010127A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
ES2285785T3 (es) 1997-09-29 2007-11-16 Point Therapeutics, Inc. Estimulacion de celulas hematopoyeticas in vitro.
AU770319C (en) 1998-05-04 2004-11-25 Point Therapeutics, Inc. Hematopoietic stimulation
ES2189423T3 (es) * 1998-06-05 2003-07-01 Point Therapeutics Inc Compuestos ciclicos de boroprolina.
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1259246A2 (en) * 2000-02-25 2002-11-27 Novo Nordisk A/S Use of dpp-iv inhibitors for the treatment of diabetes
AU2003218969A1 (en) * 2002-02-01 2003-09-02 Probiodrug Ag Modulation of t lymphocytes using dp iv inhibitors
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR20070054762A (ko) 2003-11-12 2007-05-29 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
CN1905876B (zh) 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
CA2552569C (en) 2004-01-20 2012-12-11 Novartis Ag Direct compression formulation and process
TW200604137A (en) 2004-04-27 2006-02-01 Wyeth Corp Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CN1331835C (zh) * 2005-10-18 2007-08-15 武汉大学 光活性β－羟基酮的制备方法
AU2006339348B2 (en) * 2005-12-19 2013-01-17 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2007120689A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
SI2318419T1 (sl) * 2008-06-17 2015-07-31 Millennium Pharmaceuticals, Inc. Spojine boronat estra in njihovi farmacevtski sestavki
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US9523687B2 (en) 2014-02-28 2016-12-20 Institut Pasteur Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS
MX2016015267A (es) 2014-05-20 2017-02-22 Millennium Pharm Inc Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria.
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CN108047257B (zh) * 2017-12-17 2020-03-13 沧州普瑞东方科技有限公司 一种手性n-boc-吡咯烷-2-硼酸的制备工艺
CN110452258B (zh) * 2019-09-03 2021-01-01 上海馨远医药科技有限公司 一种二肽缬氨酸硼脯氨酸盐的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
WO1991016339A1 (en) * 1990-04-14 1991-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry

Also Published As

Publication number Publication date
FI942345A (fi) 1994-05-20
IL103817A0 (en) 1993-04-04
TW232697B (es) 1994-10-21
SK59294A3 (en) 1995-02-08
PT101079A (pt) 1994-02-28
CZ124494A3 (en) 1995-07-12
NZ245207A (en) 1994-07-26
NO941905L (no) 1994-07-14
NO941905D0 (no) 1994-05-20
HUT67937A (en) 1995-05-29
CN1073946A (zh) 1993-07-07
EP0641347A1 (en) 1995-03-08
CA2123128A1 (en) 1993-05-27
FI942345A0 (fi) 1994-05-20
AU3136893A (en) 1993-06-15
AU661362B2 (en) 1995-07-20
SI9200332A (en) 1993-06-30
WO1993010127A1 (en) 1993-05-27
HU9401350D0 (en) 1994-08-29
JPH07501078A (ja) 1995-02-02

Similar Documents

Publication Publication Date Title
MX9206628A (es) Ester de prolinaboronato y metodo para su preparacion.
MX9201355A (es) Bis-naftal imidas y metodo para su preparacion.
MX24568A (es) 3-arilcarbonil-1h-indoles y procedimiento para su preparacion.
MX9205032A (es) 1,2-dihidro-2-oxo-piridinas y procedimiento para su preparacion.
MX26267A (es) Aminobenzodiacepinas y procedimiento para su prepaacion.
MX9202022A (es) Derivados de pirazina y proceso para su preparacion.
MX9102719A (es) Aparato y metodo para generar señales de cuadratura.
NO921218D0 (no) Reseptor-rensemetode
MX9207326A (es) Metodo y aparato para reensayo dirigido avanzado.
MX9204920A (es) Cianofenilpirroles y procedimiento para su obtencion.
MX9201780A (es) Eteres oximicos y procedimiento para su preparacion.
MX9203836A (es) Derivados de acido-4-amino-3-hidroxicarboxilico y proceso para su preparacion.
MX9205747A (es) Pirazolinas y procedimiento para su preparacion.
MX21243A (es) Indenoindoles y procedimiento para su preparacion.
MX9205746A (es) Pirazolinas y procedimiento para su preparacion.
MX9100811A (es) Indolonaftiridinas y procedimiento para su preparacion
MX9205821A (es) Pirimidinil- y triazinileteres y -tioeteres y procedimiento para su preparacion.
MX9202536A (es) Antibioticos tetraciclicos y procedimiento para su preparacion.
FI940403A (fi) Elliptisiinijohdannainen ja menetelmä sen valmistamiseksi
MX9204626A (es) Mensula de soporte y metodo para su fabricacion.
MX9202605A (es) Polimeros lineales y proceso para su preparacion.
MX9202327A (es) 2-aril pirroles substituidos y procedimiento para su obtencion.
MX9102324A (es) Pirimidilamidoximas substituidas y procedimiento para su obtencion.
MX9204843A (es) Pirazolinas substituidas y procedimiento para su obtencion.
MX9205346A (es) Diazacicloalcanos fosforilados y procedimiento para su obtencion.